Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.
Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.